|
-an informal group of practitioner stakeholders in
the area of pluripotent stem cell production for therapeutic use.
The Forum focuses on the procurement, manufacture and storage of human
embryonic stem cells but also considers induced pluripotent stem cells
and the manufacture and use of cell lines as advanced therapy medicinal
products.
contact
-@-sign- clinicalstemcellforum.org.uk
RecentNews:
– December 2011 update on clinical grade line development
– position
statement on embryonic stem cell patents
Mission
1. To provide a platform for those working in the procurement,
derivation, manufacture, development and management of pluripotent stem
cells (the Members) to exchange information and perspectives.
2. To assist Members in establishing agreements on best practice,
common standards, joint initiatives.
3. To give a strong unified voice to Members when engaging with
regulators, policy makers and standard setting organisations in related
fields.
4. To strengthen appreciation for the unique ethical and safety
challenges arising in the procurement and production of human embryonic
stem cells and to argue for regimes that are specific, sensitive and
appropriate to this context.
Membership
1. Membership is open to representatives of UK academic units,
Government agencies, private enterprise and clinical groups in the
field.
2. Membership of the forum is free of charge, granted at the discretion
of the Chair or the Steering Group.
3. Representatives from regulatory bodies and patient representatives
are invited to attend meetings and contribute to discussions.
4. Stakeholder representatives from other aspects cell based medicines
or outside of the UK are invited to liaise with the Forum.
Governance
1. The Forum is governed by a Steering Group consisting of one
representative from each participating institution and the Officers.
2. Officers of the Forum are the Chair, the Vice Chair, the Secretary
and the Leaders of specific Working Groups. They are elected by the
Steering Group.
3. Working Groups are the constituted for the following themes:
Procurement, Quality, Technology. These may be developed and reassigned
as deemed appropriate by the Steering Group.
4. Public-facing statements by the Forum only represent those centres
or institutions if the authorised representative expressly agrees.
Participants from:
Birmingham University, Cellartis, Edinburgh University,
HFEA, HTA, Kings College, Manchester University, MHRA, Newcastle
University, Pfizer, Roslin Cells, Sheffield University, UK Stem Cell
Bank, and affiliated NHS clinics
contact -@-sign- clinicalstemcellforum.org.uk
|
|